The structural and functional teratology of antiepileptic medications

Human Developmental Neurotoxicology

Volumn , Issue , 2006, Pages 103-130

  Adams, Jane ^a   Lantz Gavin, Jennifer Anne ^a   Janulewicz, Patricia A ^a,b  

^a UNIVERSITY OF MASSACHUSETTS BOSTON   (United States)

^b BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85122845034     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (103)

1. Wilson J. Environment and Birth Defects. New York: Academic Press, 1973.
2. Adams J, Barone S, LaMantia A, et al. Workshop to identify critical windows of exposure for children's health: neurobehavioral workshop summary. Environ Health Perspect 2000; 108:535-544.
3. Chambers CD, Braddock SR, Briggs GG, Einarson A, Johnson YR, Miller RK, Polifka JE, Robinson LK, Stepanuk K, Jones KL. Postmarketing surveillance for human teratogenicity: a model approach. Teratology 2001; 64:252-261.
4. Finnell RH, Gelineau van Waes J, Eudy JD, Rosenquist TH. Molecular basis of environmentally induced birth defects. Ann Rev Pharmacol Toxicol 2002; 42:181-208.
5. Rice D, Barone S, Jr. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect 2000; 108:511-533.
6. CDC. Epilepsy: One of the Nation's Most Common Disabling Neurological Conditions [website]. National Center for Chronic Disease Prevention and Health Promotion. Vol. 2005, 2004.
7. Janulewicz PA, Gavin JAL, Meyer E, Adams J. Pattern of psychosocial and attentional characteristics of children exposed to Phenobarbital monotherapy in utero. Neurotoxicol Teratol 2001; 23:294.
8. Rodier PM. The early origins of autism. Sci Am 2000; 282:56-63.
9. Rodier PM, Bryson SE, Welch JP. Minor malformations and physical measurements in autism: data from Nova Scotia. Teratology 1997; 55:319-325.
10. Schantz SL, Widholm JJ. Cognitive effects of endocrine-disrupting chemicals in animals. Environ Health Perspect 2001; 109:1197-1206.
11. Weiss B. Sexually dimorphic nonreproductive behaviors as indicators of endocrine disruption. Environ Health Perspect 2002; 110:387-391.
12. Vorhees CV. Principles of Behavioral Teratology. New York: Plenum Press, 1986.
13. Weiss B. Vulnerability of children and the developing brain to neurotoxic hazards. Environ Health Perspect 2000; 108:375-381.
14. Adams J. Neural and Behavioral Pathology Following Prenatal Exposure to Retinoids. New York: Marcel Dekker, 1993.
15. Delgado-Escueta AV, Janz D. Consensus guidelines: preconception counseling, management, and care of the pregnant woman with epilepsy. Neurology 1992; 42:149-160.
16. Fairgrieve SD, Jackson M, Jonas P, et al. Population based, prospective study of the care of women with epilepsy in pregnancy. BMJ 2000; 321:674-675.
17. Yerby MS. Risks of pregnancy in women with epilepsy. Epilepsia 1992; 33:S23-S27.
18. Kaneko S. Antiepileptic drug therapy and reproductive consequences: functional and morphological effects. Reprod Toxicol 1991; 5:179-198.
19. Hanson JW, Myrianthopoulos NC, Harvey MA, Smith DW. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis to the fetal hydantoin syndrome. J Pediatr 1976; 89:662-668.
20. Hanson JW, Smith DW. The fetal hydantoin syndrome. J Pediatr 1975; 87:285-290.
21. Hill RM, Verniaud WM, Horning MG, et al. Infants exposed in utero to antiepileptic drugs. A prospective study.. Am J Dis Child 1974; 127:645-653.
22. Hill RM, Verniaud WM, Rettig GM, Tennyson LM, Craig JP. Relationship Between Antiepileptic Drug Exposure of the Infant and Developmental Potential. New York: Raven Press, 1982.
23. Meadow SR. Anticonvulsant drugs and congenital abnormalities. Lancet 1968; 2:1296.
24. Speidel BD, Meadow SR. Maternal epilepsy and abnormalities of the fetus and newborn. Lancet 1972; 2:839-843.
25. Gaily E, Granstrom ML, Hiilesmaa V, Bardy A. Minor anomalies in offspring of epileptic mothers. J Pediatr 1988; 112:520-529.
26. Gaily E, Kantola-Sorsa E, Granström ML. Intelligence of children of epileptic mothers. J Pediat 1988; 113:677-684.
27. Adams J, Vorhees CV, Middaugh LD. Developmental neurotoxicity of anticonvulsants: human and animal evidence on Phenytoin. Neurotoxicol Teratol 1990; 12:203-214.
28. Middaugh LD. Phenobarbital during pregnancy in mouse and man. Neurotoxicology 1986; 7:287-301.
29. Finnell RH, Abbott LC, Taylor SM. The fetal hydantoin syndrome: answers from a mouse model. Reprod Toxicol 1989; 3:127-133.
30. Finnell RH, Chernoff GF. Mouse fetal hydantoin syndrome: effects of maternal seizures. Epilepsia 1982; 23:423-129.
31. Phillips NK, Lockard JS. A gestational monkey model: effects of phenytoin versus seizures on neonatal outcome. Epilepsia 1985; 26:697-703.
32. Janz D. Antiepileptic drugs and pregnancy: altered utilization patterns and teratogenesis. Epilepsia 1982; 23:S53-S63.
33. Majewski F, Steger M, Richter B, et al. The teratogenicity of hydantoins and barbiturates in humans with consideration on the etiology of malformations and cerebral disturbances in the children of epileptic parents. Biolog Res Pregnancy 1981; 2:37-15.
34. Granstrom ML, Hiilesmaa V. Malformations and minor anomalies in the children of epileptic mothers: preliminary results of the prospective Helsinski study. In: Janz D, Dam M, Richens A, eds. Epilepsy, Pregnancy, and the Child. New York: Raven Press, 1982:303-307.
35. Miyakoshi M, Seino M. In: Sato T, Shinagawa S, eds. Malformations in children born to mothers with epilepsy. In: Antiepileptic Drugs and Pregnancy. Amsterdam: Excerpta Medica, 1984.
36. Seino M, Miyakoshi M. Teratogenic risks of antiepileptic drugs in respect to the type of epilepsy. Folia Psychiatr Neurol Jpn 1979; 33:379-385.
37. Kaneko S, Fukushima Y, Sato T, et al. Teratogenicity of antiepileptic drugs: a prospective study. Jap Psychiatric Neurol 1986; 40:447-450.
38. Bossi L. Fetal effects of anticonvulsants. In: Morselli P, Pippenger C, Penry J, eds. Antiepileptic Drug Therapy in Pediatrics. New York: Raven Press, 1983:37-64.
39. Koch S, Losche G, Jager-Roman E, et al. Major and minor birth malformations and antiepileptic drugs. Neurology 1992; 42:83-88.
40. Holmes L, Adams J, Ryan L. Physical and behavioral consequences of in utero exposure to anticonvulsant monotherapy. Paper presented at the European Teratology Society, Hungary, 2001.
41. Nulman I, Scolnik D, Chitayat D, et al. Findings in children exposed in utero to phenytoin and carbamazepine monotherapy: independent effects of epilepsy and medications. Am J Med Genet 1997; 68:18-24.
42. Dansky LV, Finnell RH. Parental epilepsy, anticonvulsant drugs, and reproductive outcome: epidemiologic and experimental findings spanning three decades; 2: human studies. Reprod Toxicol 1991; 5:301-335.
43. Adab N, Jacoby A, Smith D, Chadwick D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiatry 2001; 70:15-21.
44. Beghi E, Annegers JF. Pregnancy registries in epilepsy. Epilepsia 2001; 42:1422-1425.
45. Holmes LB, Harvey EA, Coull BA, et al. The teratogenicity of anticonvulsant drugs. N Engl J Med 2001; 344:1132-1138.
46. Gaily E. Distal phalangeal hypoplasia in children with prenatal phenytoin exposure: results of a controlled anthropometric study. Amer J Med Genet 1990; 35:574-578.
47. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-years experience. Arch Neurol 2004; 61:673-678.
48. Kelly TE. Teratogenicity of anticonvulsant drugs: iii: radiographic hand analysis of children exposed in utero to diphenylhydantoin. Amer J Med Genet 1984; 19:445-450.
49. Kaneko S, Battino D, Andermann E, et al. Congenital malformations due to antiepileptic drugs. Epilepsy Res 1999; 33:145-158.
50. Steinhausen HC, Losche G, Koch S, Helge H. The psychological development of children of epileptic parents I. Study design and comparative findings. Acta Paediatr 1994; 83:955-960.
51. Dessens AB, Cohen-Kettenis PT, Mellenbergh GJ, et al. Association of prenatal phenobarbital and phenytoin exposure with small head size at birth and with learning problems. Acta Paediatr 2000; 89:533-541.
52. Vajda FOB, O'Brien TJ, Hitchcock A, Graham J. The Australian registry of anti-epileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci 2003; 10:543-549.
53. Jager-Roman ER, Koch S, Gopfert-Geyer I, Jacob S, Helge H. Somatic Parameters, Diseases, and Psychomotor Development in the Offspring of Epileptic Parents. New York: Raven Press, 1982.
54. Losche G, Steinhausen HC, Koch S, Helge H. The psychological development of children of epileptic parents. II. The differential impact of intrauterine exposure to anticonvulsant drugs and further influential factors. Acta Paediatr 1994; 83:961-966.
55. Vanoverloop D, Schnell RR, Harvey EA, Holmes LB. The effects of prenatal exposure to phenytoin and other anticonvulsants on intellectual function at 4 to 8 years of age. Neurotoxicol Teratol 1992; 14:329-335.
56. Adams J, Harvey EA, Holmes LB. Cognitive deficits following gestational monotherapy with phenobarbital and carbamazepine. Program for the Annual Meeting of the Neurobehavioral Teratology Society, Abstract 55, 2000.
57. Holmes LB, Wyszynski D, Mittendorf R. Evidence foran increased risk of birth defects in the offspring of women exposed to valproate during pregnancy: findings from the AED Pregnancy Registry. Am J Obstet Gynecol 2002; 187:S137.
58. Hansen DK, Holson RR. Developmental neurotoxicity of antiepileptic drugs. In: Slikker WS, Chang LW, eds. Developmental Neurotoxicology. San Diego: Academic Press, 1998:643-660.
59. Holmes LB. The teratogenicity of anticonvulsant drugs: a progress report. J Med Genet 2002; 39:245-247.
60. Majewski F, Steger M. Letter to the editors. Fetal Head Growth Retardation associated with maternal phenobarbitone/primidone and/or phenytoin therapy. Europ J Pediatr 1984; 141:188-189.
61. Mastroiacovo P, Bertollini R, Licata D. Fetal growth in the offspring of epileptic women: results of an Italian multicentric cohort study. Acta Neurol Scand 1988; 78:110-114.
62. van der Pol MC, Hadders-Algra M, Huisjes HJ, Touwen BC. Antiepileptic medication in pregnancy: late effects on the children's central nervous system development. Am J Obstet Gynecol 1991; 164:121-128.
63. Gaily E, Kantola-Sorsa E, Granstrom ML. Specific cognitive dysfunction in children with epileptic mothers. Dev Med Child Neurol 1990; 32:403-414.
64. Holmes LB, Rosenberger PB, Harvey EA, et al. Intelligence and physical features of children of women with epilepsy. Teratology 2000; 61:196-202.
65. Reinisch JM, Sanders SA, Mortensen EL, Rubin DB. In utero exposure to phenobarbital and intelligence deficits in adult men. J Am Med Associ 1995; 274:1518-1525.
66. Adams J, Holmes LB, Janulewicz P. The adverse effect profile of neurobehavioral teratogens: phenobarbital. Neurotoxicol Teratol 2004; 26:507.
67. Jones KL, Lacro RV, Johnson KA, Adams J. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989; 320:1661-1666.
68. Ornoy A, Cohen E. Outcome of children born to epileptic mothers treated with carbamazepine during pregnancy. Arch Dis Child 1996; 75:517-520.
69. Gaily E, Kantola-Sorsa E, Hiilesmaa V, et al. Normal intelligence in children with prenatal exposure to carbamazepine. Neurology 2004; 62:28-32.
70. Janulewicz P, Adams J, Dhillon R, Holmes LB. Developmental outcome of children prenatally exposed to carbamazepine. Neurotoxicol Teratol. In Press.
71. Jager-Roman E, Deichl A, Jakob S, et al. Fetal growth, major malformations, and minor anomalies in infants born to women receiving valproic acid. J Pediatr 1986; 108:997-1004.
72. Lindhout D, Schmidt D. In-utero exposure to valproate and neural tube defects [letter]. Lancet 1986; 1:1392-1393.
73. Hansen DK, Holson RR. Developmental Neurotoxicity of Antiepileptic Drugs. New York: Academic Press, 1998.
74. Wyszynski D, Nambisan M, Surve T, Alsdorf RM, Smith CR, Holmes LB. Increased rate of major malformation in offspring exposed to valproate during pregnancy. Neurology 2005; 64:961-965.
75. Robert E, Wells PG, Rosa F. Maternal valproic acid and congenital neural tube defects [letter]. Teratogenicity of Isotretinoin. Lancet 1982; 2:937.
76. Bjerkedal T, Czeizel A, Goujard J, et al. Valproic acid and spina bifida [letter]. Lancet 1982; 2:1096.
77. CDC. Recommendations for the use of folic acid to reduce the number of cases of spina bifida and other neural tube defects. MMWR 1992; 4:1-7.
78. Kozma C. Valproic acid embryopathy: report of two siblings with further expansion of the phenotypic abnormalities and a review of the literature. Am J Med Genet 2001; 98:168-175.
79. Ardinger H, Atkin J, Blackston R, Elsas L. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988; 29:171-185.
80. Ardinger HH, Atkin JF, Blackston RD, et al. Verification of the fetal valproate syndrome phenotype. Am J Med Genet 1988; 29:171-185.
81. Adab N, Kini U, Vinten J, et al. The longer term outcome of children born to mothers with epilepsy. J Neurol Neurosurg Psychiat 2004; 75:1575-1583.
82. Adab N, Jacoby A, Smith D, Chadwick D. Additional educational needs in children born to mothers with epilepsy. J Neurol Neurosurg Psychiat 2001; 70:15-21.
83. Rodier PM, Ingram JL, Tisdale B, et al. Embryological origin for autism: developmental anomalies of the cranial nerve motor nuclei. Journal Comp Neurol 1996; 370:247-261.
84. Rodier PM, Ingram JL, Tisdale B, Croog VJ. Linking etiologies in humans and animal models: studies of autism. Reprod Toxicol 1997; 11:417-422.
85. Ingram JL, Peckham SM, Tisdale B, Rodier PM. Prenatal exposure of rats to valproic acid reproduces the cerebellar anomalies associated with autism. Neurotoxicol Teratol 2000; 22:319-324.
86. Williams G, King J, Cunningham M, et al. Fetal valproate syndrome and autism: additional evidence of an association. Dev Med Child Neurol 2001; 43:847.
87. Moore SJ, Turnpenny P, Quinn A, et al. A clinical study of 57 children with fetal anticonvulsant syndromes. J Med Genet 2000; 37:489-497.
88. Bescoby-Chambers N, Forster P, Bates G. Fetal valproate syndrome and autism. Dev Med Child Neurol 2001; 43:847-852.
89. Lord C, Risi S. Frameworks and methods in diagnosing autism spectrum disorders. Mental Retard Develop Disabilities Res Rev 1998; 4:90-96.
90. Gillberg C, Persson E, Grufman M, Themnér U. Psychiatric disorders in mildly and severely mentally retarded urban children and adolescents: epidemiological aspects. Brit J Psychiat 1986; 149:68-74.
91. Shah A, Holmes N, Wing L. Prevalence of autism and related conditions in adults in a mental handicap hospital. Appl Res Mental Retard 1982; 3:303-317.
92. Lord C, Rutter M, LeCouteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Develop Disorders 1994; 24:659-668.
93. Mawer G, Clayton-Smith J, Coyle H, Kini U. Outcome of pregnancy in women attending an outpatient epilepsy clinic: adverse features associated with higher doses of sodium valproate. Seizure 2002; 11:512-518.
94. Holmes LB, Coull BA, Dorfman J, Rosenberger PB. The correlation of deficits in IQ with midface and digit hypoplasia in children exposed in utero to anticonvulsant drugs. J Pediatrics 2005; 146:118-122.
95. Honeycutt A, Dunlap L, Chen H, al Homsi G. Economic costs associated with mental retardation cerebral palsy, hearing loss, and vision impairment-United States, 2003. MMWR 2004; 53:57-59.
96. Leavitt AM, Yerby MS, Robinson N, et al. Epilepsy in pregnancy: developmental outcome of offspring at 12 months. Neurology 1992; 42:141-143.
97. Wide K, Henning E, Tomson T, Winbladh B. Psychomotor development in preschool children exposed to antiepileptic drugs in utero. Acta Paediatr 2002; 91:409-414.
98. Hirano T, Fujioka K, Okada M, et al. Physical and psychomotor development in the offspring born to mothers with epilepsy. Epilepsia 2004; 45:53-57.
99. Battino D, Kaneko S, Andermann E, et al. Intrauterine growth in the offspring of epileptic women: a prospective multicenter study. Epilepsy Res 1999; 36:53-60.
100. Hiilesma V, Teramo K, Granstrom ML, Bardy AH. Fetal head growth retardation associated with maternal antiepileptic drugs. Lancet 1981; 11:165-167.
101. Vajda F, O'Brien TJ, Hitchcock A, Graham J, Lander C. The Australian registry of antiepileptic drugs in pregnancy: experience after 30 months. J Clin Neurosci 2003; 10:543-549.
102. Gaily EK, Granstrom ML, Hiilesmaa VK, Bardy AH. Head circumference in children of epileptic mothers: contributions of drug exposure and genetic background. Epilepsy Res 1990; 5:217-222.
103. Matalon S, Schechtman S, Goldzweig G, Ornoy A. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures. Reprod Toxicol 2002; 16:9-17.